Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04958434 · ClinicalTrials.gov registry record · Phase 1
Study of TST005 in Patients With Locally Advanced or Metastatic Solid Tumors
A Phase 1 study, sponsored by Suzhou Transcenta Therapeutics Co..
- Terminated
- Registry status
- Phase 1
- Development phase
- 19
- Enrollment target
NCT04958434 is a Phase 1 study that was terminated before completion, run by Suzhou Transcenta Therapeutics Co.. The registered enrollment target is 19 participants.
The verdict
NCT04958434, a Phase 1 study, was terminated before completion, sponsored by Suzhou Transcenta Therapeutics Co..
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 19 participants
- Enrollment target
Study Summary
This is an open label Phase 1, first-in-human (FIH) study of TST005, a bi-specific antibody consisting of a PD-L1 monoclonal antibody (mAb) and a transforming growth factor beta (TGF-β) trap in subjects with locally advanced or metastatic cancers
Interventions
- DRUG TST005
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2021-06-11 |
| Est. Completion | 2023-09-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04958434
The ClinicalTrials.gov registry entry for NCT04958434 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Suzhou Transcenta Therapeutics Co., which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which TST005 is the first listed.
NCT04958434 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04958434 about?
NCT04958434 is a clinical study titled "Study of TST005 in Patients With Locally Advanced or Metastatic Solid Tumors". This is an open label Phase 1, first-in-human (FIH) study of TST005, a bi-specific antibody consisting of a PD-L1 monoclonal antibody (mAb) and a transforming growth factor beta (TGF-β) trap in subjects with locally advanced or metastatic cancers
What is the current status of trial NCT04958434?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2021-06-11. Estimated completion is 2023-09-30.
What interventions are being tested in trial NCT04958434?
The interventions under investigation include: TST005 (DRUG).
Who is sponsoring clinical trial NCT04958434?
This trial is sponsored by Suzhou Transcenta Therapeutics Co., which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.